Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C

doi:10.3892/mmr.2015.3361

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C
	Li, JF; Qu, F; Zheng, SJ; Ren, F; Wu, HL; Liu, M; Ren, JY; Chen, Y; Duan, ZP; Zhang, JL
刊名	MOLECULAR MEDICINE REPORTS
	2015-07
卷号	12 期号:1 页码:323-330
关键词	sphingolipids hepatitis C virus hepatic fibrosis lipid liver biopsy
ISSN号	1791-2997
DOI	10.3892/mmr.2015.3361
文献子类	Article
英文摘要	The plasma profile of sphingolipids in hepatic fibrosis patients with chronic hepatitis C (CHC) is rarely considered at present. The association between plasma sphingolipids and severe fibrosis in CHC remains an obscure area of research. The aim of the present study was to assess the plasma profile of sphingolipids and to examine the association between plasma sphingolipids and severe fibrosis in CHC, in order to identify potential novel markers of severe fibrosis in CHC. A cohort of 120 treatment-naive patients with CHC were included in the present study. Liver biopsies were performed and routine serological indicators were measured. Plasma sphingolipids were detected using high performance liquid chromatography tandem mass spectrometry. A total of 44 plasma sphingolipids were detected. Plasma hexosylceramide (HexCer; d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/22:0) were shown to be significantly different in patients with CHC between those with and without severe fibrosis (Metavir F 3; P<0.05). HexCer (d18:1/12:0) was observed to be closely associated with severe fibrosis in CHC [odds ratio (OR)=1.03] following adjustment for confounding variables in a multivariate analysis. HexCer (d18:1/12:0) had diagnostic value for severe fibrosis in CHC [area under the curve (AUC)=0.69]. In patients with CHC who had developed significant fibrosis (Metavir F 2), HexCer (d18:1/12:0) remained closely associated with severe fibrosis (OR=1.08) in this subgroup. In addition, HexCer (d18:1/12:0) had sufficient diagnostic ability (AUC=0.73) to distinguish severe fibrosis in patients with CHC with significant fibrosis. In conclusion, the present study indicated that plasma HexCer (d18:1/12:0) exhibits a close correlation with severe hepatic fibrosis in CHC, particularly in patients who have significant fibrosis. Additionally, HexCer (d18:1/12:0) may be a potential marker of severe hepatic fibrosis in CHC.
学科主题	Oncology ; Research & Experimental Medicine
出版地	ATHENS
资助项目	国家科技重大专项
项目编号	National Science and Technology Key Project [2012ZX10002004-006, 2012ZX10004904-003-001, 2013ZX10002002-006] ; Ministry of Science and Technology of the People's Republic of China [2012ZX09301002-006] ; High Technical Personnel Training Item in the Beijing Health System [2011-3-083] ; Special Scientific Research Fund for Beijing Health Development [2011-2018-04] ; YouAn Scientific Research Fund for Liver Disease and HIV/AIDS [BJYAH-2011-045]
语种	英语
WOS记录号	WOS:000358134400046
资助机构	MOST
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178584]
专题	第一临床医学院_期刊论文
通讯作者	Duan, ZP (reprint author), Capital Med Univ, Beijing YouAn Hosp, Artificial Liver Ctr, 8 Xitoutiao,Youwai St, Beijing 100069, Peoples R China.
推荐引用方式 GB/T 7714	Li, JF,Qu, F,Zheng, SJ,et al. Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C[J]. MOLECULAR MEDICINE REPORTS,2015,12(1):323-330.
APA	Li, JF.,Qu, F.,Zheng, SJ.,Ren, F.,Wu, HL.,...&Duan, ZP .(2015).Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C.MOLECULAR MEDICINE REPORTS,12(1),323-330.
MLA	Li, JF,et al."Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C".MOLECULAR MEDICINE REPORTS 12.1(2015):323-330.